MoonLake Immunotherapeutics (NASDAQ: MLTX)’s stock price has plunge by 18.68relation to previous closing price of 41.16. Nevertheless, the company has seen a 26.62% surge in its stock price over the last five trading sessions. reuters.com reported 2025-06-02 that Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.
Is It Worth Investing in MoonLake Immunotherapeutics (NASDAQ: MLTX) Right Now?
The 36-month beta value for MLTX is at 1.23. Analysts have varying views on the stock, with 12 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MLTX is 52.94M, and currently, shorts hold a 11.41% of that float. The average trading volume for MLTX on June 03, 2025 was 413.10K shares.
MLTX’s Market Performance
The stock of MoonLake Immunotherapeutics (MLTX) has seen a 26.62% increase in the past week, with a 15.43% rise in the past month, and a 21.22% gain in the past quarter. The volatility ratio for the week is 2.81%, and the volatility levels for the past 30 days are at 3.55% for MLTX. The simple moving average for the last 20 days is 24.26% for MLTX stock, with a simple moving average of 6.97% for the last 200 days.
Analysts’ Opinion of MLTX
Many brokerage firms have already submitted their reports for MLTX stocks, with Wolfe Research repeating the rating for MLTX by listing it as a “Outperform.” The predicted price for MLTX in the upcoming period, according to Wolfe Research is $61 based on the research report published on May 19, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see MLTX reach a price target of $67. The rating they have provided for MLTX stocks is “Outperform” according to the report published on March 18th, 2025.
Goldman gave a rating of “Buy” to MLTX, setting the target price at $82 in the report published on January 17th of the current year.
MLTX Trading at 26.00% from the 50-Day Moving Average
After a stumble in the market that brought MLTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.15% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at MLTX starting from BVF PARTNERS L P/IL, who sale 2,000,000 shares at the price of $50.00 back on Oct 04 ’24. After this action, BVF PARTNERS L P/IL now owns 1,287,768 shares of MoonLake Immunotherapeutics, valued at $100,003,200 using the latest closing price.
Sturge Simon, the Director of MoonLake Immunotherapeutics, sale 171,000 shares at $53.72 during a trade that took place back on Oct 04 ’24, which means that Sturge Simon is holding 171,980 shares at $9,186,120 based on the most recent closing price.
Stock Fundamentals for MLTX
Current profitability levels for the company are sitting at:
- -1210.31 for the present operating margin
- 0.22 for the gross margin
The net margin for MoonLake Immunotherapeutics stands at -1428.72. The total capital return value is set at -0.25. Equity return is now at value -30.57, with -27.01 for asset returns.
Based on MoonLake Immunotherapeutics (MLTX), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -1.85. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is 6848.37.
Currently, EBITDA for the company is -119.58 million with net debt to EBITDA at 1.65. When we switch over and look at the enterprise to sales, we see a ratio of 28304.87. The receivables turnover for the company is 0.03for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.11.
Conclusion
In conclusion, MoonLake Immunotherapeutics (MLTX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
